New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18, offering both glycemic control and weight loss ...

Glucagon-like peptide-1 (GLP-1) injections like Wegovy (semaglutide) and Zepbound (tirzepatide) have revolutionized the weight-loss medication market. But oral GLP-1 pills are on the horizon and ...

Tirzepatide is a dual GLP-1 and GIP receptor agonist ... Section 5 – User Journey and Market Tone Public discussions around GLP-1 weight management increasingly focus on the patient journey - from ...

MariTide, a new drug from Amgen, helped some people with obesity lose up to 20% of their body weight. In a phase 2 trial, a new GLP-1 drug helped people lose up to 20% of their body weight over a year ...

Eli Lilly's GLP-1 drug Zepbound is poised to "dominate" the weight loss market, according to BMO. Weekly prescription drug data shows Zepbound has seen a surge in uptake since its recent FDA approval.

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.